Replimune, Inc.
Clinical trials sponsored by Replimune, Inc., explained in plain language.
Replimune, Inc.
REPL
NASDAQ
Biopharmaceutical company developing oncolytic immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cold sore virus turned into cancer killer? early trial underway Results expected Oct 2026 (estimated)
- Can a tweaked herpes virus help fight cancer? early trial underway Results expected Nov 2026 (estimated)